HRT Sales Show Tactical Moves, Not Value Loss, as Aditxt Advances Immuno‑Therapies
Discover how Aditxt’s NF‑κB‑targeted immunosuppressive platform may reshape autoimmune therapy, with key Phase II results, insider trading insights, and regulatory milestones.
3 minutes to read